Search results for "Chronic Liver Disease"

showing 5 items of 165 documents

The GALAD Score as Potential Screening Test for Hepatocellular Carcinoma in Nonalcoholic Steatohepatitis: An International Multicenter Study

2019

The prevalence of nonalcoholic steatohepatitis (NASH) is rising rapidly and is currently the most common chronic liver disease in Western populations. Hepatocellular carcinoma (HCC) is a major complication of NASH and the current performance of screening approaches based on ultrasound shows limitations. To facilitate earlier diagnosis, this international multicenter study, with eight German and one Japanese center participating, tests the potential benefit of applying the biomarkers AFP, AFP-L3, DCP and related scores for HCC screening in NASH patients. In the retrospective German cohort, 126 NASH patients with newly diagnosed HCC and 231 NASH control patients without HCC were enrolled. In …

medicine.medical_specialtyeducation.field_of_studybusiness.industryPopulationInstitutional review boardmedicine.diseaseChronic liver diseasedigestive system diseasesHelsinki declarationMulticenter studyInternal medicineHepatocellular carcinomaCohortMedicineAFP-L3businesseducationneoplasmsSSRN Electronic Journal
researchProduct

Non-invasive Diagnostic Approach to NASH: Biological Markers

2020

Non-alcoholic fatty liver disease (NAFLD) prevalence and incidence are dramatically increasing in parallel with the epidemics of both obesity and type 2 diabetes, accounting for the most growing cause of chronic liver disease, of hepatocellular carcinoma and of end-stage liver disease leading to liver transplantation. Natural history studies clearly demonstrated that among NAFLD population, those with non-alcoholic steatohepatitis (NASH) have a double risk of fibrosis progression, and that the severity of liver fibrosis is the main driver of hepatic and extrahepatic prognosis. Consistently, the availability of non-invasive markers to be used in NAFLD patients represents a relevant medical n…

medicine.medical_specialtyeducation.field_of_studymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentFatty liverPopulationDiseaseLiver transplantationmedicine.diseaseChronic liver diseaseGastroenterologyLiver diseaseInternal medicineLiver biopsymedicineSteatohepatitiseducationbusiness
researchProduct

Risk Factors Regarding Portal Vein Thrombosis in Chronic Liver Disease

2020

Abstract The portal vein thrombosis (PVT) is one of the most frequent vascular diseases of the liver, with a high rate of morbidity and mortality. The most common causes of the PVT are hepatic cirrhosis, hepatobiliary neoplasms, inflammatory and infectious abdominal diseases, and myeloproliferative syndromes.(1,2) The natural progress of the PVT has as a result portal hypertension which leads to splenomegaly and the formation of portosystemic collateral vessels, as well as gastroesophageal, duodenal and jejunal varices. Ultrasonography, especially Doppler ultrasound, is the most widely used imaging method to asses, supervise and diagnose PVT in patients with hepatopathies. The purpose of ac…

medicine.medical_specialtygenetic structuresbusiness.industryGeneral MedicineChronic liver diseasemedicine.diseasebehavioral disciplines and activitiesGastroenterologyPortal vein thrombosis03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisInternal medicinemental disordersmedicine030211 gastroenterology & hepatologybusinesshuman activitiespsychological phenomena and processesActa Medica Transilvanica
researchProduct

Rare <i>Atg7</i> Genetic Variants Predispose to Severe Fatty Liver Disease

2021

Background&Aims: Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease and has a strong heritable component. The aim of this study was to identify new genes involved in NAFLD pathogenesis. Methods: We examined rare variants captured by whole-exome sequencing in individuals with severe fibrosis or hepatocellular carcinoma due to NAFLD (severe NAFLD, n=301) after variant prioritization.  We replicated the results in the UK Biobank and the Liver biopsy cohort (n=2268). Results: We observed an enrichment of the p.P426L variant (rs143545741 C>T; OR=7.2, 2.3-17.3; p C; MAF=0.060 vs. 0.035; OR=1.7, 1.2-2.5; p=0.003). In the UK Biobank cohort, the p.V471A variant wa…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryFatty livermedicine.diseaseChronic liver diseaseGastroenterologyPathogenesisLiver diseaseBallooning degenerationLiver biopsyInternal medicineHepatocellular carcinomamedicineSteatosisbusinessSSRN Electronic Journal
researchProduct

Interconnections among inflammation, chronic liver disease and HIV: understanding the hepatoprotective effects of the antiretroviral drug rilpivirine

2022

INTRODUCCIÓN Durante las últimas décadas, la utilización de la terapia antirretroviral combinada (TARc) para combatir la infección por el virus de la inmunodeficiencia humana (VIH) ha convertido esta enfermedad en una patología crónica. A pesar de que la TARc ha mejorado enormemente la calidad de vida de los pacientes, según diversos estudios epidemiológicos, estos pacientes envejecen antes y sufren de enfermedades relacionadas con la edad como cáncer, osteoporosis, enfermedades metabólicas (diabetes mellitus y enfermedad hepática) y patologías neurodegenerativas aparecen a edades más tempranas que la población no infectada. Los mecanismos responsables de este fenómeno aún no se conocen, si…

rilpivirineinflammationUNESCO::CIENCIAS MÉDICASHIVchronic liver disease:CIENCIAS MÉDICAS [UNESCO]
researchProduct